Record Order Intake and Backlog Growth
Booked nearly $1.1 billion of orders in 2025, a 26% increase versus 2024, and drove a 36% increase in backlog year-over-year (boosted by 2025 order growth plus Paragon backlog). Q4 orders rose 62%, including ~$140 million of large opportunity awards.
Strong Nuclear Power and Nuclear Medicine Performance
Nuclear power organic revenue grew ~11% in 2025 and nuclear medicine organic revenue grew more than 13%, both cited as drivers for expected double-digit organic growth in 2026 for those end markets.
Large Opportunity Pipeline
More than $400 million of large opportunities identified for potential awards in 2026 (including ~$200 million carryover from 2025), with the company noting a strong 'right to win' on these projects and nearly half of new opportunities coming from Paragon.
Robust 2026 Guidance
2026 full-year guidance calls for total revenue growth of 22–24% (5–7% organic growth excluding FX and acquisitions), adjusted EBITDA of $285–300 million (25–26% margin, ~90 bps expansion), adjusted free cash flow $155–175 million, and adjusted EPS $0.50–0.57 (midpoint would be $0.61 excluding stock-based comp).
Improved Profitability and Margin Expansion
Full-year adjusted EBITDA grew to $227.9 million, up 12% YoY, with full-year margins expanding ~90 basis points. Q4 adjusted EBITDA of $77.6 million was up 11.5% versus Q4 2024; procurement and operating-leverage initiatives delivered meaningful margin improvement (procurement ~100 bps in 2025).
Step Change in Free Cash Flow and Debt Costs
Adjusted free cash flow for 2025 totaled $131 million—roughly double 2024's $65 million—and represented a 57% conversion of adjusted EBITDA. Capital structure moves reduced pro forma cost of debt to ~2.9% in 2025 down from 7.4% in 2024.
SMR Momentum and Strategic M&A
SMR-related orders totaled $39 million in 2025 (vs $17 million in 2023–2024 combined) with ~ $10 million already seen in January 2026. Strategic acquisitions (Paragon and CertRec) broaden North American nuclear power exposure, add capabilities (e.g., CertRec's regulatory SaaS and data), and are expected to unlock synergies and commercial leverage.